Core Viewpoint - The article discusses the ongoing efforts by the Chinese government to combat corruption in the pharmaceutical and healthcare sectors, emphasizing a comprehensive approach to address various forms of misconduct and enhance regulatory oversight [1][2]. Group 1: Regulatory Framework - The National Health Commission and 14 other ministries have issued a notification outlining key points for correcting misconduct in the pharmaceutical procurement and healthcare services for 2025 [1]. - This year's focus includes strengthening oversight of "key minority" and critical positions, as well as enhancing the detection of new, variant, and hidden issues in the healthcare sector [1][2]. - The notification emphasizes the importance of "penetrating" audits to cover the pharmaceutical production end, ensuring compliance and preventing illicit benefits [2][3]. Group 2: Compliance and Auditing - The notification encourages pharmaceutical companies to adopt compliance management practices, referencing guidelines released by the State Administration for Market Regulation [2]. - A focus on "penetrating audits" aims to break down traditional regulatory barriers by integrating micro-level insights with macro-level oversight [3]. - The establishment of a joint auditing mechanism among various regulatory bodies is recommended to enhance information sharing and collaborative oversight [3]. Group 3: Addressing Misconduct in Healthcare - The notification outlines a zero-tolerance policy for violations of medical ethics, emphasizing strict accountability for healthcare professionals [4][6]. - Specific areas of focus for misconduct include patient privacy, genetic testing, assisted reproduction, and medical aesthetics, with a commitment to maintaining a high-pressure environment against corruption [5][6]. - The regulation of internet healthcare practices will target illegal activities such as online medical advertising and fraudulent marketing tactics [5][6]. Group 4: Long-term Measures and Implementation - The notification proposes a linkage between medical ethics evaluations and various professional incentives, such as job appointments and salary distributions, to foster a positive industry environment [7]. - The overall strategy is divided into four parts with 15 specific actions aimed at reinforcing anti-corruption efforts and enhancing the integrity of the healthcare system [7]. - A collaborative approach among departments is emphasized to ensure effective implementation of the outlined measures [7].
事关医药反腐,14部委划重点!
第一财经·2025-06-16 08:51